Introduction {#s1}
============

5q-associated spinal muscular atrophy (SMA) is one of the most common neuromuscular diseases in childhood and is caused by homozygous deletion or less frequently other mutations in the survival motor neuron 1 gene (*SMN1*). The protein encoded by this gene, SMN, is ubiquitously expressed and eukaryotic cells are not viable without SMN protein. Despite the homozygous deletion in *SMN1*, patients with SMA are viable because of the existence of insufficient intrachromosomal duplications of *SMN1*, the *SMN2* gene, centromeric to *SMN1*. However, a base pair substitution in exon 7 and the intron silence sequence in intron 7 of *SMN2* lead to an altered splicing, and consequently exon 7 is missing in \~90% of final mRNAs. Skipping of exon 7 leads to an unstable, non-functional SMN protein, which is immediately degraded ([@B1]). The clinical phenotype of the disease is more or less devastating, depending largely on the number of *SMN2* copies ([@B2]). Although SMN is expressed in all tissues, lower amounts of SMN primarily affects lower motoneurons (MN) leading to muscle weakness and muscle atrophy ([@B3]). SMA was originally thought to be a pure motoneuron disease (MND), but recent evidence suggests a multisystem involvement ([@B4]). The preferential involvement of proximal muscle groups also suggests differences in vulnerability against SMN deficiency of different MN pools. In SMA animal models it has been demonstrated that distinct motor units have different susceptibility to the lack of SMN ([@B5], [@B6]). Additionally, we recently showed that denervation of hand muscles in SMA patients is not equally distributed. In contrast to amyotrophic lateral sclerosis (ALS), adult SMA type 2 (SMAII), and 3 (SMAIII) patients presented with a typical denervation pattern of the hand muscles (reversed split hand) ([@B7]). SMN is ubiquitously expressed, and SMN levels are reduced in different tissues in SMA animal models including spinal cord, brain, kidney, liver, heart and muscle ([@B8]). A very recent study on health insurance data revealed numerous non-neuromuscular phenotypes which had been diagnosed in the cardiovascular, gastrointestinal, metabolic, reproductive, and skeletal systems in pre-diagnostic SMA ([@B9]). Fitting to that, neuropathological studies revealed widespread neuronal degeneration also in dorsal root ganglia, thalamus, cerebral cortex, basal ganglia, pigmented nuclei, brainstem and cerebellum in severely affected SMA type 1 patients ([@B10], [@B11]). Studies on sural nerve biopsies revealed sensory nerve pathology in SMA type 1 patients, but not in type 2 or 3 ([@B12]) and cases of vascular necrosis/vascular thrombosis were reported in SMA type 1 patients ([@B13], [@B14]). While congenital heart disease is a phenomenon of SMA type 1 ([@B15]), involvement of the heart revealed by electrocardiography seems to be evident in all types of SMA ([@B16]). Recently, dysfunction of energy metabolism and increased levels of leptin were found in SMA type 1 to 3 patients, which was associated with disease severity and decreased motor function. It was hypothesized that neuronal degradation of hypothalamic cells or an increase in fat content by muscle remodeling could be the cause of the highly prevalent hyperleptinemia in SMA patients ([@B17]).

To our knowledge, a systematic evaluation of the prevalence and significance of non-motor symptoms (NMS) in adult SMA has not yet been reported. The aim of this study was therefore to assess the NMS burden in adult patients with SMAII and SMAIII with the NMS questionnaire (NMSQuest).

Methods {#s2}
=======

Participants
------------

We analyzed data from 70 genetically confirmed SMAII and SMAIII as well as 59 healthy controls (for details see [Table 1](#T1){ref-type="table"}). We only included healthy subjects, if no physical or psychological disabilities/diagnoses were reported, none of them suffered from a chronic devastating disease. Data were collected from five different centers of expertise in motoneuron diseases: Technische Universität Dresden (Germany), Ulm University (Germany), Technical University of Munich (Germany), University of Rostock (Germany) and University Medicine Göttingen (Germany). All patients and controls gave their informed consent and study approval was obtained by the local ethics committees (EK393122012; A 2014-0021; EK19/12, 2012; P001660A; 2019-0054, 10/2/17).

###### 

Demographic and clinical characteristics of the study populations.

                                  **Controls**   **SMA**
  ------------------------------- -------------- ------------------------
  Number                          59             70
  Ratio of female (%)             57.9           45.7
  Age (yr)                        35.3 ± 9.2     35.9 ± 10.9
  Subtypes (n)                    --             SMAII (27) SMAIII (43)
  Nusinersen treatment (yes/no)   0/59           40/30
  Wheelchair-bound/ambulatory     0/59           49/21
  HFMSE                           --             19.7 ± 21.7
  RULM                            --             19.5 ± 13.2
  ALSFRS-R                        --             31.1 ± 8.6

Assessments
-----------

The NMSQuest is a 30-item self-completed questionnaire featuring responses as "yes" and "no" to each item and was originally designed and validated for Parkinson\'s disease patients ([@B18]--[@B20]). It is a widely used screening questionnaire also used in amyotrophic lateral sclerosis (ALS) and cervical dystonia ([@B21]--[@B23]). Its 30 items were termed according to the publication of Chadhuri et al. ([@B18]) and can be grouped into 9 domains (digestive, urinary, memory, perceptions, mood, sex, cardiovascular, sleep, and miscellaneous). "Total NMS score" was defined by the sum of all positive ("yes") answers of the 30 items. We additionally recorded data of age, gender, revised ALS-Functional-Rating Scale (ALSFRS-R), Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM).

Statistical Analysis
--------------------

As the samples were not normally distributed according to the Kolmogorov-Smirnov test, the statistical comparisons of data between groups were performed using the non-parametric Mann--Whitney *U*-test (MWU) for total NMS score and age. Pearson\'s chi-squared test (χ2) was carried out for a comparison of gender distribution and for a comparison of the proportion of "yes" and "no" responses between patients and controls for each single item. Spearman rank correlation coefficients were used to examine correlations between total NMS score and clinical characteristics with a correlation coefficient of rho \<0.3 considered as a weak, rho = 0.3--0.59 a moderate, and rho ≥0.6 a strong correlation. Data were analyzed using the software SPSS 21.0 (SPSS Inc., Chicago, IL, USA) and Statistica 13.2 \[StatSoft (Europe) GmbH, Hamburg, Germany\]. If not mentioned otherwise, all data are displayed as means ± standard deviation (SD). Significance level was set at *p* \< 0.05. Correction for multiple testing was not applied as the study is merely exploratory, hypothesis-generating, thus a previous hypothesis was not proposed.

Results {#s3}
=======

Demographic and Clinical Characteristics
----------------------------------------

NMSQuest data from 70 adult SMAII and SMAIII patients and 59 age/sex matched controls were analyzed and compared. Demographic and clinical characteristics of study populations are shown in [Table 1](#T1){ref-type="table"}. 57.1% of the patients were under nusinersen treatment to the time point of survey. Thirty percent of patients were ambulatory and 70% full-day wheelchair-bound. Except for the item "sex difficulty" and "changes of sex drive," which was not answered by 3 patients and 1 control, all other questions were fully answered of all subjects. Two of the controls reported extremely high numbers of NMS (18 and 23 items, respectively) and were classified as extreme values and therefore removed from the analysis. SMA and control group did not differ significantly in age (*p* = 0.85) or gender (*p* = 0.17). Most patients were severely affected by the disease (HFMSE: 19.7 ± 21.7; RULM 19.5 ± 13.2, ALSFRS-R: 31.1 ± 8.6).

NMS in SMA Patients
-------------------

Total NMS were not significantly different between SMA and controls (*p* = 0.07) ([Figure 1A](#F1){ref-type="fig"}). The sum of NMS ranged from 0 to 12 items in SMA patients with a median of 3 items and in controls from 0 to 13 items with a median of 2 items. Total NMS score was not significant different (*p* = 0.45) between nusinersen treated patients (*n* = 40, median 3, range 0 to 12 items) and untreated patients (*n* = 30, median 2.5, range 0 to 12 items). Total NMS of SMA patients did not correlate with disease severity scores (HFMSE rho = −0.02, *p* = 0.87, *N* = 65; RULM rho = −0.06, *p* = 0.61, *N* = 66; ALSFRS-R rho = −0.17, *p* = 0.21, *N* = 59) ([Figure 1B](#F1){ref-type="fig"}). However, SMA patients complained about the items "swallowing difficulties," "falling," and "swelling legs" significantly more frequently compared to controls ([Figure 1C](#F1){ref-type="fig"}, for details see [Table 2](#T2){ref-type="table"}). "Excessive sweating" was 10% more frequently reported in the SMA group, but was not significantly different to controls (*p* = 0.09). SMA patients who reported the item "swallowing difficulties" had significant lower scores on ALSFRS-R (Yes: 24.1 ± 4.6, No: 32.8 ± 8.6, *p* \< 0.0001), RULM (Yes: 6.2 ± 6.9, No: 20.2 ± 13.2, *p* = 0.016) and HFMSE (Yes: 2.4 ± 4.0, No: 19.4 ± 21.5, *p* = 0.042) compared to SMA patients who did not complain for "swallowing difficulties." HFMSE (Yes: 8.7 ± 11.8, No: 21.5 ± 23.5, *p* = 0.038), but not ALSFRS-R (Yes: 28.4 ± 7.0, No: 33.03 ± 9.2, *p* = 0.087) or RULM (Yes: 14.9 ± 12.6, No: 19.5 ± 13.8, *p* = 0.077) were significantly lower in SMA patients who reported "swelling legs" compared to SMA patients who did not. SMA patients who reported "swelling legs" were significantly more often full-day wheelchair-bound (Yes: 22 of 26 were wheelchair-bound, No: 27 of 44 were wheelchair-bound, *p* = 0.04). "Falling" was reported from SMA patients with higher scores in HFMSE (Yes: 43.0 ± 15.6, No: 11.8 ± 17.7, *p* \< 0.001), ALSFRS-R (Yes: 41.4 ± 4.6, No: 29.4 ± 8.0, \<0.001) and RULM (Yes: 31.5 ± 7.8, No: 15.3 ± 12.8, *p* \< 0.001). "Falling" was significantly more often reported from ambulatory patients (Yes: 10 of 12 patients were ambulatory, No: 47 of 58 were wheelchair-bound, *p* \< 0.001). ALSFRS-R, HFMSE und RULM were not significantly different between SMA patients who reported "excessive sweating" and patients who did not.

![Patient-reported prevalence of non-motor symptoms (NMS) in adult 5q spinal muscular atrophy (SMA). Total NMS score **(A)** depicted as box plot and ratio of response "yes" of single items **(C)** depicted as histograms were compared between SMA (black) and controls (controls) (white). Correlation of total NMS score and ALSFRS-R is shown as scatterplot **(B)**. Spearman rank correlation coefficient (rho). ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001, n.s., not significant.](fneur-10-01098-g0001){#F1}

###### 

Comparison of NMS between controls and SMA patients.

                                                                 **Distribution of response "yes" in percentages**   **Chi-squared-test**   
  -------------------------------------------------------------- --------------------------------------------------- ---------------------- -------
  Dribbling                                                      0                                                   4.3                    0.114
  Taste/smelling difficulties                                    1.8                                                 0                      0.266
  Swallowing difficulties[^\*\*\*^](#TN2){ref-type="table-fn"}   1.8                                                 24.3                   0.000
  Vomiting                                                       19.3                                                10.0                   0.135
  Constipation                                                   14.0                                                12.9                   0.846
  Bowel incontinence                                             0                                                   0                      n.c.
  Bowel emptying                                                 12.3                                                18.6                   0.333
  Urgency                                                        17.5                                                8.6                    0.130
  Nocturia[^\*\*^](#TN1){ref-type="table-fn"}                    14.0                                                1.4                    0.006
  Pains                                                          5.3                                                 10                     0.324
  Weight loss                                                    1.8                                                 7.1                    0.155
  Difficulties of remembering                                    17.5                                                17.1                   0.953
  Loss of interest                                               8.8                                                 8.6                    0.968
  Hallucinations                                                 1.8                                                 0.0                    0.266
  Concentration difficulties                                     22.8                                                20.0                   0.701
  Sad, blues                                                     28.1                                                35.7                   0.359
  Anxiety                                                        7.0                                                 17.1                   0.087
  Changes of sex drive                                           10.5                                                11.4                   0.872
  Sex difficulty                                                 1.8                                                 5.7                    0.262
  Felling dizzy                                                  15.8                                                15.7                   0.991
  Falling [^\*\*^](#TN1){ref-type="table-fn"}                    0                                                   17.1                   0.001
  Daytime sleepiness                                             7.0                                                 2.9                    0.272
  Insomnia                                                       40.4                                                31.4                   0.296
  Intense vivid dreams                                           15.8                                                18.6                   0.680
  Acting out during dreams                                       8.8                                                 14.5                   0.324
  Restless legs                                                  14.0                                                21.4                   0.282
  Swelling legs[^\*\*\*^](#TN2){ref-type="table-fn"}             3.5                                                 37.1                   0.000
  Excessive Sweating                                             7.0                                                 17.1                   0.087
  Diplopia                                                       0                                                   2.9                    0.198
  Delusions                                                      1.8                                                 1.4                    0.883

Significantly different items are labeled with

*p \< 0.01*,

*p \< 0.001; n.c., non-calculable*.

Comparison of SMAII and SMAIII revealed no significant differences in total NMS score (*p* = 0.99). The sum of NMS ranged from 0 to 12 in SMA patients with median 3 in both groups. Significant differences were only found for two items. The item "falling" was more frequently reported by SMAIII patients, however it has to be taken into account that SMAII are not ambulatory (per definition) and therefore have generally a lower risk to fall. This is highlighted by the fact that the item falling is also strongly depending on the severity score HFMSE. The second difference between SMAII and SMAIII patients was the item "acting out during dreams," which was more frequently reported by SMAII, however still not significantly different to controls (*p* = 0.06). All other items are not significantly different between SMAII and SMAIII (see [Table 3](#T3){ref-type="table"}).

###### 

Comparison of NMS between SMAII and SMAIII.

                                                              **Distribution of response "yes" in percentages**   **Chi-squared-test**   
  ----------------------------------------------------------- --------------------------------------------------- ---------------------- -------
  Dribbling                                                   7.4                                                 2.3                    0.307
  Taste/smelling difficulties                                 0                                                   0                      n.c.
  Swallowing difficulties                                     29.6                                                20.9                   0.409
  Vomiting                                                    11.1                                                9.3                    0.806
  Constipation                                                11.1                                                14.0                   0.729
  Bowel incontinence                                          0                                                   0                      n.c.
  Bowel emptying                                              22.2                                                16.3                   0.534
  Urgency                                                     7.4                                                 9.3                    0.783
  Nocturia                                                    0                                                   2.3                    0.425
  Pains                                                       11.1                                                9.3                    0.806
  Weight loss                                                 7.4                                                 7.0                    0.946
  Difficulties of remembering                                 18.5                                                16.3                   0.809
  Loss of interest                                            7.4                                                 9.3                    0.783
  Hallucinations                                              0                                                   0                      n.c.
  Concentration difficulties                                  22.2                                                18.6                   0.713
  Sad, blues                                                  40.7                                                32.6                   0.487
  Anxiety                                                     25.9                                                11.6                   0.122
  Changes of sex drive                                        18.5                                                7.0                    0.140
  Sex difficulty                                              7.4                                                 4.7                    0.629
  Felling dizzy                                               22.2                                                11.6                   0.236
  Falling[^\*^](#TN3){ref-type="table-fn"}                    3.7                                                 25.6                   0.018
  Daytime sleepiness                                          0                                                   4.7                    0.256
  Insomnia                                                    25.9                                                34.9                   0.432
  Intense vivid dreams                                        26.0                                                14.0                   0.210
  Acting out during dreams[^\*^](#TN3){ref-type="table-fn"}   25.9                                                7.1                    0.031
  Restless legs                                               14.8                                                25.6                   0.285
  Swelling legs                                               37.0                                                37.2                   0.988
  Excessive Sweating                                          14.8                                                18.6                   0.682
  Diplopia                                                    0                                                   4.7                    0.256
  Delusions                                                   0                                                   2.3                    0.425

Significantly different items are labeled with

*p \< 0.05; n.c., non-calculable*.

Discussion {#s4}
==========

SMA pathophysiology is caused by homozygous deletion or mutations in the *SMN1* gene, which encodes the ubiquitously expressed SMN protein. However, the phenotype of the disease is dominated by lower MN symptoms, therefore the disease is termed "spinal muscular atrophy." So far, only few studies focused on non-motor involvement in this disease, mainly focused on children with SMA type 1. This is the first study reporting a comprehensive assessment of NMS burden in adult SMA patients.

Patient-reported prevalence of NMS was generally low and, did not---in total---differ significantly from healthy controls and also did not correlate with the severity scores ALSFRS-R, HFMSE and RULM. However, patients in the SMA group complained significantly more frequently about the items "swallowing difficulties," "falling," and "swelling legs." "Swallowing difficulties" were reported by patients who were more severely affected, as indicated by the specific severity scores, as compared to those who were less affected, which may be explained by more prominent bulbar involvement in more severe disease stages. "Falling" was significantly more often complained by patients who were less severely affected by the disease and ambulatory which is explained by the fact that more severely disabled patients are unable to walk and wheelchair-bound and therefore have a lower risk to fall. "Swelling legs" was reported from patients who had lower HFMSE scores. "Swallowing difficulties" and "falling" can be attributed to motor symptoms, but "swelling legs" is highly prevalent and might be a real NMS in SMA. Several reasons could explain this NMS in SMA. It might be a consequence of venous insufficiency due to abnormal posture and/or immobility, as many of the adult patients are fully wheelchair-bound and/or due to decreased muscle strength of the lower limbs with reduced venous muscle pump. Fitting to this hypothesis, patients in this study who complained for "swelling legs" were significantly more frequently full-day wheelchair-bound. On the other hand, it may be related to cardiac insufficiency. Disease involvement of the cardiac muscle has been demonstrated in animal models and patients with severe forms of SMA ([@B15], [@B24], [@B25]) and there are indirect indications to cardiac alterations reflected by electrocardiographic changes in all SMA types ([@B16]). Evaluation of cardiac function is not regularly included in routine health care of these patients. Functional and histological studies are necessary to further study cardiac involvement in adult patients with SMAII and SMAIII.

Neuropsychiatric related complaints like "anxiety," "loss of interest," "concentration difficulties," "feeling dizzy" and "insomnia" were reported in a frequency comparable to healthy controls and were not significantly increased in SMA patients. This may appear surprising, because the disease reduces self-reliance and mobility and often leads to dependency on medical aids and comprehensive medical support. However, it fits to the general impression that most adult SMA patients show a high degree of resilience and no signs of adaptive disorders or depression. This observation is confirmed by a recent published study, where Fischer et al. showed that psychological well-being in adult SMA patients was comparable to that of healthy controls and was unrelated to sociodemographic variables or illness characteristics ([@B26]).

Urinary symptoms, including "bowel incontinence," "bowel emptying incomplete," "urgency," and "nocturia," were only rarely reported by SMA patients. Only a few SMA patients reported "nocturia," and this was significantly less frequent compared to controls. It could be concluded, that urinary symptoms are not present in these patients. The reason why the item "nocturia" was significantly less frequently reported might be that patients have learned to cope with their motor disabilities, which do not allow them to reach the bathroom in an acceptable time during night.

Comparing groups of patients with SMAII and SMAIII revealed no significant differences in total NMS score. As expected, the item "falling" was significantly more frequent in SMAIII, because all SMAII patients were wheelchair-bound and had therefore a lower risk to fall. The item "acting out during dreams" was more frequent in SMAII, however still not significantly different from controls.

Taken together, patient-reported prevalence of NMS in adult patients with SMA was generally low, arguing for a low perceived burden of other than the motor system. However, "swelling legs" might be a relevant NMS in SMA and its etiology has to be investigated in further studies. Further studies including structured interviews and detailed instrument-based measurements of NMS are warranted to unravel the amount of actual and subclinical NMS in adult SMA.

There are several limitations of this study. First, the screening for NMS was based on a self-rating questionnaire, which was originally designed for Parkinson\'s disease patients and was not validated for SMA. Previous studies revealed normal quality of life and well-being in adult SMA patients even though these patients were physically severely disabled ([@B26], [@B27]). Such coping mechanisms possibly reduce the self-perception of NMS and thus might result in a difference between perceived and actual NMS. Based on a recent published study on health insurance datasets it can be assumed that NMS could be detected in increased rates if investigated by detailed diagnostic examination ([@B9]). However, datasets of health insurance are based on diagnoses made by physicians without the detailed knowledge how these have been made, thus are also biased. For example, general physical weakness and creatine kinase elevation might have been misinterpreted as a cardiac disease and not acknowledged as first symptoms of a yet undiagnosed SMA. Nevertheless, we cannot exclude that the frequency of some of the NMS mentioned above may in fact be higher in adult SMA patients, if it was ascertained either by a structured interview or by diagnostic procedures. Therefore, further studies to differ between perceived and actual NMS are needed.
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